课题基金 / 基金详情

Midcareer Investigator Award in Patient-Oriented Research in Acute Lung Injury

Midcareer Investigator Award in Patient-Oriented Research in Acute Lung Injury
急性肺损伤以患者为导向的研究中的职业生涯中期研究员奖
批准号:
9279235
负责人:
Lorraine B Ware
金额:
$16.23万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-09 至 2021-03-31

项目摘要

项目成果

Lorraine B Ware的其他基金

相似基金

相关文献

中文摘要
翻译
 描述(由申请人提供):本次续展申请以患者为中心的研究生涯中期研究员奖的总体目标是使Ware博士能够继续建立和扩大她在以患者为中心的ARDS研究中的研究和指导计划。这一奖项将使她能够继续将大量受保护的时间投入到她目前的导师身上,并扩大她的导师范围,将新的博士后实习生和医学生包括在内。此外,这一奖项的支持将使Ware博士能够扩大她的指导范围,包括加强她的指导对象的指导技能的新努力,以确保为下一代以患者为导向的研究人员提供强有力的指导。此外,威尔博士的以患者为导向的研究计划将在新的和新的方向上扩展。具体地说,她将专注于无细胞血红蛋白的释放,以及结合珠蛋白的遗传异质性如何决定无细胞血红蛋白对肺移植后原发移植物功能障碍(ARDS的一种形式)的影响。这些研究基于令人信服的初步数据,表明术前血浆无细胞血红蛋白水平升高与肺移植受者发生原发移植物功能障碍密切相关,并且结合珠蛋白2:2基因与严重脓毒症患者ARDS的发生有关。有三个具体目标。目的1将验证如下假设,即血浆游离血红蛋白水平与肺移植患者发生PGD的风险相关,并且这种关系在再灌流时被FiO2改变。目的2将验证一个假设,即受体结合珠蛋白2:2基因型与肺移植后PGD的高发病率相关,并且这种关系被无细胞血红蛋白水平所修正。最后,目标3将通过量化脂质过氧化、内皮和肺上皮损伤和炎症的生物标志物,并测试它们与手术前后无细胞血红蛋白水平和结合珠蛋白2:2基因型的相关性,来确定无细胞血红蛋白增加移植物功能障碍的风险的机制。这些研究将有助于更好地了解无细胞血红蛋白和结合珠蛋白基因型对移植物功能障碍风险的影响,并可能导致改进供者选择标准和供受者配型。此外,这些研究可能导致预防和治疗原发性移植物功能障碍和非移植相关ARDS的新疗法。
英文摘要
 DESCRIPTION (provided by applicant): The overall goal of this renewal application for a Midcareer Investigator Award in Patient-Oriented Research is to enable Dr. Ware to continue to build and expand her research and mentoring programs in patient-oriented research in ARDS. This award will allow her to continue to devote significant protected time to her current mentees as well as to expand her mentoring to include new postdoctoral trainees and medical students. In addition, the support of this award will allow Dr. Ware to expand the reach of her mentoring to include new efforts to enhance the mentoring skills of her mentees in order to assure strong mentoring for future generation of patient-oriented researchers. In addition, Dr. Ware's program in patient-oriented research will be expanded in new and novel directions. Specifically, she will focus on how release of cell-free hemoglobin, and genetic heterogeneity in haptoglobin, the primary endogenous scavenger of cell-free hemoglobin, determine the effects of cell-free hemoglobin on primary graft dysfunction, a form of ARDS, after lung transplantation. These studies are based on compelling preliminary data demonstrating that elevated pre-operative plasma levels of cell-free hemoglobin are strongly associated with development of primary graft dysfunction in lung transplant recipients and that the haptoglobin 2:2 genotype is associated with development of ARDS in severe sepsis. There are three specific aims. Aim 1 will test the hypothesis that plasma cell-free hemoglobin levels are associated with risk of PGD in patients undergoing lung transplantation and that this relationship is modified by FiO2 at reperfusion. Aim 2 will test the hypothesis that recipient haptoglobin 2:2 genotype is associated with a higher incidence of PGD after lung transplantation and that this relationship is modified by cell-free hemoglobin levels. Finally, Aim 3 will determine the mechanism by which cell-free hemoglobin potentiates the risk of primary graft dysfunction by quantifying biomarkers of lipid peroxidation, endothelial and lung epithelial injury and inflammation and testing their associations with pre- and post-operative cell-free hemoglobin levels and haptoglobin 2:2 genotype. These studies will lead to a better understanding of the influence of cell-free hemoglobin and haptoglobin genotypes on risk of primary graft dysfunction and may lead to improved donor selection criteria and donor-recipient matching. In addition, these studies may lead to new treatments for prevention and treatment of both primary graft dysfunction and non-transplant associated ARDS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The MUltidimenSional phenotyping In Critical care (MUSIC) Consortium: A pathway to precision medicine at the bedside
Mechanisms of organ dysfunction and recovery in the Acetaminophen and Ascorbate Trial in Sepsis
Peri-operative factors that drive cell-free hemoglobin-mediated primary graft dysfunction
Mechanisms of organ dysfunction and recovery in the Acetaminophen and Ascorbate Trial in Sepsis
海外基金